Articles tagged with Oncology
A study found that fewer than half of U.S. adults are aware of the link between alcohol and cancer, highlighting a need for increased awareness and action. The findings emphasize the importance of reducing the alcohol-related cancer burden in the US.
Researchers have identified FAM111B as a promising candidate for glioma treatment. The study found that FAM111B overexpression enhances glioma malignancy through the PI3K/AKT pathway, providing a novel avenue for therapeutic intervention.
Researchers from Mayo Clinic Comprehensive Cancer Center will present practice-changing studies on chemotherapy approaches, AI applications in oncology, and new therapies for breast and melanoma. The event will feature 59 abstracts highlighting advancements in cancer care.
The Experimental Drug Development Centre's EBC-129, an antibody-drug conjugate targeting pancreatic cancer, has received FDA fast track designation. The treatment is undergoing Phase 1 clinical trials and aims to provide new treatment options for patients with solid tumours.
The National Comprehensive Cancer Network (NCCN) honors individuals who champion access to high-quality, patient-centered cancer care. This year's recipients include Drs. Nadeem Abu-Rustum and Louis Nabors for their excellence in engagement and dedication to shaping cancer treatment recommendations.
Researchers examined baseline characteristics of adolescent and young adult (AYA) cancer survivors seen in oncology primary care clinic, finding high rates of comorbidities and cardiovascular disease. They also studied the overexpression of IRAK4 protein in acute myeloid leukemia (AML) cells, with potential implications for treatment.
The University of Houston has launched a $3M Cancer Immunotherapy Biomarker Core to accelerate early diagnosis and treatment response in cancer. The core will offer comprehensive targeted proteomic cancer biomarker screens, enabling researchers to identify better biomarkers for cancer.
Dana-Farber researchers have identified several promising interventions for breast and colorectal cancer, including a potential new treatment approach for stage III deficient DNA mismatch repair colon cancer and improved strategies for treating rare and aggressive forms of brain lymphoma. The findings will be presented at the 2025 Annu...
The European Society for Medical Oncology (ESMO) has released the latest version of the ESMO-MCBS scale, which measures the clinical benefit of cancer treatments. The new version incorporates 13 critical amendments to improve evaluation and accuracy, with a focus on patient preferences and toxicity annotations.
A study published in PNAS reveals that colorectal cancer cells utilize a protein called TBX3, which regulates embryo development, to contribute to their aggressiveness and metastasis. The discovery opens up possibilities for developing targeted therapies to prevent tumor cell spread.
A new study published in Blood Cancer Discovery found that certain gene mutations and the maturity of leukemia cells affect how patients respond to venetoclax and hypomethylating agents. Researchers identified a subtype of acute myeloid leukemia with worse outcomes, particularly those without the NPM1 mutation.
Researchers developed an artificial intelligence technique that detects DNA fragments in patient blood to monitor treatment response. The ARTEMIS-DELFI approach was found to be more effective and simpler than existing methods, allowing for quicker identification of patients who are not responding to therapy.
A randomized controlled trial found that additional imaging techniques such as fast MRI and contrast mammography can detect early-stage cancers in women with dense breasts that were missed by mammograms. The study showed a cancer detection rate of 1.7% for fast MRI and 1.9% for contrast mammography, compared to 0.4% for ultrasound.
A new liquid biopsy blood test called HPV-DeepSeek achieved 99% sensitivity and specificity for diagnosing cancer in asymptomatic patients. The test detected fragments of the viral genome and other features in the blood, outperforming current methods in detecting HPV-associated head and neck cancers.
A team of researchers at Baylor College of Medicine identified six flavonoids that kill bladder cancer cells, including compounds that cause DNA damage and disrupt energy supply. The study uses Cell Painting technology to analyze large-scale drug screening data sets on a standard desktop computer.
US survivors of adolescence and young adult cancer experience significantly worse mental health outcomes into middle age and older adulthood. Cancer clinicians should acknowledge this mental health burden and take steps to address it.
A study found that blood cancer survivors are more likely to face financial hardship and take fewer medications due to high-cost immunotherapy treatments. Financial strain affects both Medicare-insured and uninsured patients, highlighting the need for better financial support and policy strategies.
A cohort study found that long-term survival was similar among patients with low-risk early-stage cervical carcinoma who underwent simple, modified, or radical hysterectomy. These findings support the use of simple hysterectomy in select patients.
The American Society for Radiation Oncology (ASTRO) will host its 67th Annual Meeting in San Francisco from September 27 to October 1, 2025. The meeting will feature over 2,500 research presentations and posters on advances in radiation oncology and non-cancer indications.
A study by Mass General Brigham found that patients with glioblastoma who received gabapentin lived longer than those who didn't. The medication was shown to confer a four-month survival benefit, with patients on gabapentin surviving an average of 16 months compared to 12 months for those without the drug.
Researchers at the University of Chicago Medicine discovered a new phenomenon where high doses of radiation cause growth in existing metastatic tumors. The 'badscopal effect' is attributed to increased production of amphiregulin, which weakens the immune system and makes cancer cells more resistant.
Researchers identified changes in stromal tissue associated with increased aggressive breast cancer risk and poorer survival rates among women with benign breast disease. The study used machine learning to detect subtle changes in breast tissue samples from over 9,000 women.
A new study uses explainable machine learning to predict metastasis and mortality in children with medulloblastoma, identifying key immune factors driving risk. The model provides a transparent approach to prognostic accuracy and supports personalized clinical decision-making.
City of Hope's largest outpatient facility, Hope Plaza, brings together cancer experts for highly individualized care. The center offers cutting-edge technologies, over 735 clinical trials, and integrated supportive services.
The University of Texas at Arlington's nursing and physics team has developed a system to study alpha radiation, improving the effectiveness of radiation therapy. The team's research was recognized with the Best in Physics award at the American Association of Physicists in Medicine's annual meeting.
A large-scale study published in eClinicalMedicine found that transmasculine and gender-diverse individuals who use testosterone for an average of five years do not have an increased risk of gynecological cancer. The research, which followed 1955 participants, suggests that hormone therapy may be safe for this group.
Researchers at MD Anderson Cancer Center have made breakthroughs in understanding pancreatic cancer metastases and identifying potential biomarkers for treatment-resistant pancreatic cancer. A comprehensive spatial map provides insights into lineage shifts in cancer cells transitioning from primary tumors to organ-specific metastases.
City of Hope experts will present new cancer treatment approaches, targeted therapies and lifestyle changes aimed at reducing cancer risk and improving survival. Highlights include discussions on biomarkers in kidney cancer, symptom science and palliative care.
Abnormal fungal colonization in pancreatic ductal adenocarcinoma (PDA) promotes tumor growth and activates the host complement system, suggesting Malassezia as a potential driver of cancer development.
The NCCN Policy Summit brought together experts to discuss ways to strengthen collaborative cancer care, from early detection to survivorship. Key findings include the need for better communication and coordination between primary care and oncology providers.
A new study published in the Journal of the National Cancer Institute suggests that artificial intelligence can help detect interval breast cancers earlier, potentially reducing their rates by 30%. The research used AI software to analyze mammograms and identify subtle signs of cancer that were missed by radiologists.
A new study introduces the RAPID-RT study, which uses a rapid-learning approach to evaluate the impact of treatment modifications in radiotherapy. The technique aims to reduce cardiac toxicity and improve survival in lung cancer patients by minimising dose to the top of the heart, a previously identified risk area.
Researchers from the University of Southampton engineered a new type of super-strong antibody that triggers a stronger response from the immune system compared to naturally produced antibodies. The study confirms that making subtle increases in rigidity stimulates immune activity, creating a powerful immune response against disease.
Pennington Biomedical welcomes Dr. Adithya Hari, MD, with expertise in nuclear oncology and translational science, strengthening cancer research and patient-centered innovation in Louisiana. He will establish a research program focused on nuclear medicine and dedicate time to direct patient care through a clinical partnership.
This study found a decline in racial and ethnic disparities in receipt of ERBB2-targeted therapies among older Medicare beneficiaries with ERBB2-positive breast cancer. The narrowing of disparities may be attributed to changes in healthcare practices or policies over time.
Researchers at TUM developed an AI-powered algorithm to predict kidney damage in prostate cancer patients undergoing lutetium-177 PSMA therapy. Early detection could enable personalized treatment adjustments to prevent organ damage.
Researchers at Karolinska Institutet have identified new biomarkers in urine that can indicate the presence and severity of prostate cancer with high precision. The findings surpass current blood biomarker PSA in terms of diagnostic accuracy.
A phase II trial found that PD-1 blockade with dostarlimab induced complete tumor clearance and resolved the need for surgery in patients with early-stage mismatch repair-deficient cancers. This approach showed promise for preserving organs, improving quality of life, and potentially increasing survival.
Insilico Medicine is presenting significant achievements in cancer therapy and immunology, including AI-powered discovery of potential therapies and novel solutions for unmet needs. The company's Pharma.AI platform has received IND clearance for 10 molecules, with promising results in Phase 2a clinical studies.
A cohort study found that women with screen-detected estrogen receptor–positive or human epidermal growth factor receptor 2–negative breast cancer who underwent prior screening had an earlier stage of diagnosis and lower breast cancer mortality compared to those who did not undergo prior screening.
Current computed tomography (CT) imaging may lead to up to 103,000 future cancers over a patient's lifetime. If practices persist, CT-associated cancer could account for 5% of all new diagnoses annually.
Living in disadvantaged neighborhoods is associated with a higher risk of mortality from breast cancer in Black women. Community-level interventions aimed at reducing environmental stressors and improving access to high-quality cancer care could help reduce racial disparities in breast cancer survival.
Researchers developed an IRRS model to predict prognosis and immunotherapy response in CRC patients by integrating clinical data and transcriptomic profiles. The model identified a robust multi-gene signature associated with improved survival and immune infiltration in low-risk patients.
Jeffrey E. Lee, M.D. has been appointed Chief Medical Executive at MD Anderson, succeeding Dr. Peter WT Pisters. With over 34 years of tenure, Lee will lead the institution's efforts in research, patient care, prevention, and education. He brings a strong track record of leadership and clinical expertise to the role.
A new surgical technique called NeuroSAFE has been shown to preserve erectile function in men with prostate cancer, with 39% of patients experiencing no or mild dysfunction after treatment. This is compared to 23% of those who received standard surgery.
Patients from American Indian and Black communities are less likely to have elevated CA-125 levels at diagnosis, suggesting current thresholds may miss diverse patients. Inclusive diagnostic guidelines are needed to address disparities in ovarian cancer diagnosis and treatment.
A multicenter cohort study found that higher adherence to annual lung cancer screening was associated with increased overall and early-stage lung cancer detection rates. However, adherence decreased over time, suggesting it is a critical quality metric for lung cancer screening.
This cohort study found that geographic access to cancer care is associated with guideline-recommended treatment for early-stage non–small cell lung cancer. Socially marginalized patients benefited from improved treatment outcomes and prognosis when accessing care in their local area.
Impact Journals is proud to exhibit at the AACR Annual Meeting 2025, featuring its esteemed journals Aging-US, Oncotarget, Oncoscience, and Genes & Cancer. The meeting highlights significant advancements in cancer research, aligning with Impact Journals' mission to disseminate impactful scientific research.
A team of researchers from Chiba University has developed a novel radioactive drug that targets and treats metastatic melanoma. The treatment utilizes astatine-211 labeled peptide analog, which shows high accumulation in tumors, rapid clearance from non-target organs, and significant tumor suppression.
Breast and colorectal cancer screening rates have recovered from pandemic-related declines, surpassing pre-pandemic estimates. Cervical cancer screening rates remain below pre-pandemic levels, indicating a persistent trend of declining early-stage diagnoses.
Cervical cancer incidence increased in rural US counties, with higher rates among white women, likely due to lower screening coverage and diagnostic care utilization. Rural areas may experience heightened access barriers, contributing to lower HPV vaccine uptake.
The ESMO Targeted Anticancer Therapies Congress 2025 features state-of-the-art presentations on new targets, tumour-agnostic drug development, and the role of artificial intelligence in cancer treatment. The congress also highlights recent study results and their potential impact on precision medicine.
A recent study found that Medicare decedents with advanced cancer often receive aggressive care at the end of life, despite a lack of support. The study highlights the need for improved quality of care and more comprehensive approaches to address this issue.
The joint venture will unite the nation's largest comprehensive pediatric system with a top pediatric cancer program and the nation's leading comprehensive cancer center. The collaboration aims to accelerate improved outcomes for patients in Texas and around the world, increasing access to clinical trials and innovative treatments.
Cancer cells work together to source nutrients from their environment, a cooperative process that can be targeted for treating cancer. Researchers identified key enzymes and mechanisms behind this cooperation, including the enzyme CNDP2, which can be inhibited by the drug bestatin.
A cross-sectional study found that perceived stress, inadequate social support, racial discrimination, and neighborhood deprivation negatively impacted systemic and tumor immunity in Black women. These findings may inform prevention and public health interventions for cancer health disparities.
Research teams have made significant breakthroughs in understanding cancer mechanisms, including the role of genetic mutations and tumor microenvironment interactions. These findings hold promise for developing targeted therapies and improving cancer treatment outcomes.
Researchers from Notre Dame and a Mexican hospital created a cooperative cancer monitoring tool to track children's health in low-income communities. The SaludConectaMX system aims to alleviate the challenges faced by families with pediatric cancer, including fragmented healthcare systems and limited access to resources.
Researchers developed a method to detect H3K27M-mutant droplets from circulating tumor DNA in cerebrospinal fluid, enabling early diagnosis and treatment of leptomeningeal disease. This approach improved survival rates for patients with diffuse midline gliomas.